NonSurgical Debridement 75A50126C00002
Summary
AI-generated · Apr 03, 2026Procure an FDA-approved enzymatic debridement product for non-surgical wound care and support development of a next-generation product to enhance preparedness.
Award has been issued to VERICEL CORPORATION for this effort, with a contract value of $196,869,966.
This acquisition will allow BARDA to support procurement of an FDA-approved enzymatic debridement product and support development of a next generation product for increased preparedness value.
From Award Notice posted on Apr 02, 2026Notice history
1Details
Award Information
Award Notices
Posted: Apr 02, 2026
This acquisition will allow BARDA to support procurement of an FDA-approved enzymatic debridement product and support development of a next generation product for increased preparedness value.
Awardees
| Company Name | UEI | CAGE Code | Location |
|---|---|---|---|
| VERICEL CORPORATION | WHK8B1525XA7 | 7GED2 | Cambridge, MA |
Contacts
Agency
Place of Performance
USA